Первично-рефрактерные формы и рецидивы лимфомы Ходжкина
Диссертация
Проблема клинического течения, лечения, прогноза резистентных форм и рецидивов заболевания сохраняет свою актуальность и в настоящее время. Пациенты с рефрактерным течением и рецидивами ЛХ представляют достаточно разнородную группу с точки зрения прогноза в зависимости от исходной стадии, характера первичного лечения, сроков возникновения, а также от наличия различных неблагоприятных факторов… Читать ещё >
Содержание
- ВВЕДЕНИЕ
- ГЛАВА I. Обзор литературы
- ГЛАВА II. Материалы и методы
- ГЛАВА III. Эффективность и токсичность программ МОРР, АВУБ и ВЕАСОРР-базовый у первичных пациентов ЛХ с ИЛУ АБ стадиями с неблагоприятным прогнозом
- ГЛАВА IV. Первично-рефрактерные формы лимфомы Ходжкина
- ГЛАВА V. Рецидивы лимфомы Ходжкина
- ГЛАВА VI. Обсуждение результатов
- ВЫВОДЫ
Список литературы
- Архипов A.A. Применение производных нитрозомочевины в печени рецидивов лимфогранулематоза // Дис.. канд. мед. наук. Л. — 1988. — 242 с.
- Владимирская Е.Б. Биологические основы противоопухолевой терапии. М.: Агат-Мед, 2001. 110 с.
- Волкова О.В., Елецкий Ю. К. Основы гистологии с гистологической техникой. М.: Медицина, 1971. — 272 с.
- Дьердь К. Практическая микротехника и гистохимия. Изд-во акад. наук Венгрии, 1962. — 399 с.
- Ковригина, A.M. Морфологическая и иммуногистохимическая дифференциальная диагностика лимфомы Ходжкина и крупноклеточных лимфом // Автореф. дис.. канд. мед. наук. М. -2006.-50 с.
- Кондратьева H.H. Особенности течения I-II стадий лимфогранулематоза с поражением средостения // Автореф. дис.. канд. мед. наук. М. — 2001. — 27с.
- Коржевский Д.Э. Применение гематоксилина в гистологической технике // Морфология. 2007. — Т. 132, № 6. — С. 77 — 81.
- Лавдовский, М.Д. Основания к изучению микроскопической анатомии человека и животных СПб., 1887. — 398 с.
- Лилли, Р. Патогистологическая техника и практическая гистохимия -М.: Мир, 1969. 645 с.
- Лимфомы: Научно-практическое издание / Под ред. A.M. Гранова, Н. В. Ильина СПб.: ФГУ «РНЦРХТ», 20Ю.-272с.
- Мерабишвили, В.М. Выживаемость онкологических больных. СПб.: фирма Коста, 2006. — 440 с.
- Меркулов, Г. А. Курс патогистологической техники. Л.: Медицина, 1969.-340 с.
- Ромейс Б. Микроскопическая техника // М. Изд-во иностранной лит., 1954.-718 с.
- Роскин Г. И. Микроскопическая техника. М.: Совет, наука, 1957. -467 с.
- Сапожников, А.Г. Гистологическая и микроскопическая техника. -Смоленск.: САУ, 2000. 476 с.
- Саркисов Д.С., Петров Ю. Л. Микроскопическая техника: Рук. для врач, и лаборантов М.: Медицина, 1996. — 468 с.
- Соболев, Л.В. Основы патолого-гистологической техники СПб.: В. Безобразовъ и Ко, 1910. — 242 с.
- Фрайштат, Д.М. Реактивы и препараты для микроскопии: Справ. М., 1980.-480 с.
- Шендерова, И. А. Роль дистанционной лучевой терапии в лечениирецидивов лимфомы Ходжкина // Автореф. дис.. канд. мед. наук.-СПб., 2005.-23 с.
- Akpek G., Ambinder R.F., Piantadosi S. et al. Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma // J. Clin. Oncol. -2001.-Vol. 19.-P. 4314−4321.
- Aleman В., van den Belt-Dusebout A.W., Klokman W.J. et al. Long-term cause-specific mortality of patient treated for Hodgkin’s disease // J. Clin. Oncol. -2003. Vol. 21. — P. 3431−3439.
- Amini R.M., Glimelius В., Gustavsson A. et al. A population-based study of the outcome for patients with first relapse of Hodgkin’s lymphoma // Eur. J. Haematol. 2002. — Vol. 68. — P. 225−232.
- Anderlini P. New frontiers in allogeneic transplantation for Hodgkin’s lymphoma // Haematologica. 2007. — Vol. 92. — P. 19. (Abstr. 1063).140
- Anderson J.E., Litzow M.R., Appelbaum F.R. et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: The 21-year Seattle experience // J. Clin. Oncol. 1993. — Vol. 11. — P. 2342−2350.
- Andre M., Henry-Amar M., Pico J.L. et. al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin' s disease induction failure: a case-control study // J. Clin. Oncol. 1999. — Vol.17. -P. 222.
- Antic D., Tomin D., Cemerikic V., Boskovic D. The correlation between the immunostains for P53, Ki67, PRB, BCL-6, EBV-LMP expression and classical prognostic factors in Hodgkin lymphoma // Haematologica. 2007. — Vol. 92 (s5). — P. 46 (Abstr. P045).
- Aparacio J., Segura A., Garcera S. et al. ESHAP is an active regimen for relapsing Hodgkin’s disease // Ann. Oncol. 1999. — Vol. 10.-P. 593−595.
- Axdorph U., Sjoberg J., Grimfors G. et al. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin’s disease // Ann. Oncol. 2000. — Vol. 11. — P. 1405−1411.
- Bargonetti J. Manfredi J.J. Multiple roles of the tumor suppressor p53 // Curr. Opin. Oncol.-2002.-Vol. 14 -№ l.-P. 86−91.
- Bartlett N.L., Niedzwiecki D., Johnson L. et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59 804 // Ann. Oncol. 2007. — Vol. 18. -P.1071−1079.
- Borst P., Jonkers J., Rottenberg S. What makes tumors multidrug resistant? // Cell Cycle. 2007. — Vol. 6. — P. 2782−2787.141
- Brada M., Eeles R., Ashley S. et al. Salvage radiotherapy in recurrent Hodgkin’s disease // Ann. Oncol. 1992. — Vol. 3.-P. 131−135.
- Brice P. Managing relapsed and refractory Hodgkin lymphoma // Br. J. Haematol. 2008. — Vol. 141. — P. 3−13.
- Brice P., Bastion Y., Divine M. et al. Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients // Cancer (Philad.). 1996. -Vol. 78.-P. 1293−1299.
- Brierley J.D., Rathmell A.J., Gospodarowicz M.K. et al. Late relapse after treatment for clinical stage I and II Hodgkin’s disease // Cancer. 1997. -Vol. 79.-P. 1422−1427.
- Brink A.A., Oudejans J.J., van den Brule A.J. et al. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin’s disease: involvement of apoptosis resistance? // Mod. Pathol. -1998.-Vol. 11.-P. 376−383.
- Byrne B.J., Gockerman J.P. Salvage therapy in Hodgkin’s lymphoma // Oncologist. 2007. — Vol. 12. — P. 156−167.
- Campbell B., Wirth A., Milner A. et al. Long-term follow-up of salvage radiotherapy in Hodgkin’s lymphoma after chemotherapy failure // Int. J. Radiat. Oncol. Biol. Phys. 2005. — Vol. 63. — PI538−1545.
- Canellos G.P., Anderson J.R., Propert J.R. et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD // N. Engl. J. Med. -1992. Vol. 327. — P. 1478−1484.
- Canellos G.P., Gollub J., Neuberg D. et al. Primary systemic treatment of advanced Hodgkin’s disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up // Ann. Oncol. 2003. — Vol. 14. — P. 268−272.
- Canioni D., Deau-Fischer B., Taupin P. et al. Prognostic Significance of new immunohistochemical marcers in Refractory classical Hodgkin lymphoma: a study of 59 cases // PLoS ONE.- 2009. Vol. 4. № 7. — P. e6341.
- Castagna L., Magagnoli M., Balzarotti M. et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin’s lymphoma: A monocenter prospective study // Am. J. Hematol. 2007. — Vol. 82. — P. 122−127.
- Constans M., Sureda A., Terol M.J. et al. Autologous stem cell transplantation for primary refractory Hodgkin’s disease: results and clinical variables affecting outcome // Ann. Oncol. 2003. — Vol. 14. — P.745−751.
- Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant // Am. J. Hematol. 2008. — P. 326−333.
- Czyz J., Szydlo R., Knopinska-Posluszny W et al. Treatment for primary refractory Hodgkin' s disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy // Bone Marrow Transplant. -2004. Vol. 33. — P. 1225−1229.
- Dalu D., Viviani S., Di Nicola M. et al. IGEV an effective salvage and mobilizing regimen in refractory or relapsed Hodgkin lymphoma: the istituto nazionale tumori experience // Haematologia. 2010. — Vol. 95. — P. S31−32. (Abstr. PI07).
- Devizzi L., Santoro A., Bonfante V. et al. Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin’s disease // Ann. Oncol. 1994. — Vol. 5. — P.817−820.
- Diehl V., Franklin J., Pfreundschuh M., Lathan B. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease // N. Engl. J. Med. 2003. — Vol. 348. — P. 2386−2395.
- Duggan D.B., Petroni F.R., Johnson J.L. et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial // J. Clin. Oncol. 2003. — Vol. 21. — P. 607−614.
- Engert A., Diehl V., Franclin J. et al. Escaleted-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study // J. Clin. Oncol. 2009. — Vol. 27. — P. 4548−4554.
- Evens A.M., Altman J.K., Mittal B.B. et al. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin’s lymphoma // Ann. Oncol. 2007. — Vol. 18. — P. 679−688.
- Fehniger T.A., Larson S., Trinkaus K. et al. A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin lymphoma // Blood. 2008. — Vol.112. — P. 2595.
- Franklin J., Diehl V. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin’s disease: final analysis of the HD9 randomized trial of the GHSG // Ann. Oncol. 2002. — Vol. 13 (suppl. 1). — P. 98−101.144
- Fung H.C., Stiff P., Schriber J. et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma // Biol. Blood Marrow Transplant. 2007. — Vol. 13. -P. 594−600.
- Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic enaluations in human malignancies // Semin Cancer Biol. -1990. Vol. 1. — № 3. — P. 99−206.
- Gerdes J., Schwab U., Lemke H. Stein Producing of a mouse monoclonal antibody reactive with a human nuclear antigen associated witn cell proliferation // Int. J. Cancer.- 1983.-Vol. 31. № 1.- P. 13−20.
- Gisselbrecht C., Mounnier N., Andre M. et al. How to define intermediate stage in Hodgkin’s lymphoma? // Eur. J. Haematol. 2005. — Vol. 75. (suppl. 66).-P. 111−114.
- Glimelius I., Molin D., Amini R.M. et al. Bulky disease is the most important prognostic factor in Hodgkin Lymphoma stage IIB // Eur. J. Haematol. -2003. -Vol. 71. P. 327−333.
- Gobbi P.G., Pieresca C., Ghirardelli M.L. et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin’s disease // Blood. 1998. — Vol. 91. — P. 2704−2712.
- Goodman K.A., Riedel E., Serrano V. et al. Long-term outcome of survivors of autologous hematopoietic cell transplantation for refractory and relapsed
- Hodgkin lymphoma // Haematologica. 2007. — Vol. 92. — P. 48. (Abstr. P050).
- Gopal A.K., Metcalfe T.L., Gooley T.A. et al. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: The Seattle experience // Cancer. 2008. — Vol. 113. — P. 1344−1350.
- Hasenclever D., Diehl V. A prognostic score for advanced hodgkin’s disease // N. Engl. J. Med. -1998. Vol. 339. — P. 1506−1514.
- Horning S.J. Primary refractory Hodgkin’s disease // Ann. Oncol. 1998. -Vol. 9(suppl. 5).-P. 97−101.
- Horning S.J., Fanale M., deVos S. et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort // Ann. Oncol.-2008.-Vol. 19 (suppl. 4).-P. ivl20. (Abstr. 118).
- Horning S.J., Hoppe R.T., Breslin S. et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: Mature results of a prospective clinical trial. // J. Clin. Oncol. 2002. — Vol. 20. — P. 630−637.
- Horwich A., Specht L., Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin’s disease who have relapsed after initial treatment with radiotherapy alone // Cancer. 1997. — Vol. 33. — P.848−853.
- James P. Salvage therapy in Hodgkin’s lymphoma // Oncologist. 2009. -Vol. 14.-P. 425−432.
- Johnston P.B., Ansell S.M., Colgan J.P. et al. mTOR inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with everolimus (RAD001) // Blood.-2007.-Vol.110.-P.2555.
- Josting A, Franklin J, May M. et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German lymphoma study group // J. Clin. Oncol. -2002. Vol. 20. — P. 221−230.
- Josting A., Engert A., Diehl V, et al. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin’s disease // Ann. Oncol. 2002. — Vol. 13. — P. 112−116.
- Josting A., Muller H., Borchmann P. et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma // J. Clin. Oncol. 2010. -Vol. 28.-P. 5074−5080.
- Josting A., Nogova L., Franklin J. et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group // J. Clin. Oncol. -2005. Vol. 23. — P. 1522−1529.
- Josting A., Rueffer U., Franklin J. et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group // Blood. 2000. — Vol. 96. — P. 1280−1286.
- Korsmeyer S. J. Bcl-2 initiates a new category of oncogenes: regulators of cell death // Blood. 1992.- Vol. 80. — № 4. — P. 879−86.
- Kuruvilla J., Nagy T., Zadeh S. et al. Outcome of gemcitabine-based salvage chemotherapy and autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma // Haematologica. 2007. — Vol. 92. — P. 77. (Abstr. PI36).
- Kuruvilla J., Song K., Mollee P. et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin’s lymphoma // Hematology. -2006.-Vol. 11.-P. 25−29.
- Lazarus H.M., Rowlings P.A., Zhang M.J. et al. Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry // J. Clin. Oncol. 1999. -Vol. 17.-P. 534−545.
- Levine A. J. P 53, the cellular gatekeeper for growth and division // Cell.1997.-Vol. 88. -№ 3.-P. 323−331.
- Linch D.C., Winfield D., Goldstone A.H. et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease//Lancet. 1993.-Vol. 341.-P. 1051−1054.
- Little R., Wittes R.E., Longo D.L. et al. Vinblastine for recurrent Hodgkin’s disease following autologous bone marrow transplant // J. Clin. Oncol.1998.-Vol. 16.-P. 584−588.
- Lohri A., Barnett M., Fairey R.N. et al. Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988 // Blood. 1991. -Vol.77. — P. 2292−2298.
- Martinelli G., Cocorocchio E., Peccatori F. et al. ChlVPP/ABVVP a firstline hybrid combination chemotherapy for advanced Hodgkin’s lymphoma: A retrospective analysis // Br. J. Haematol. 2004. — Vol. 125. — P. 584−589.
- Martinez C., Canals C., Alessandrino E.P. et al. Relapse of Hodgkin' s lymphoma after autologous stem cell transplantation: identification of prognostic factors predicting outcome // Haematologica. 2010. — Vol. 95. -P. S26. (Abstr. C088).
- Mendler J.H., Friedberg J.W. Salvage therapy in Hodgkin’s lymphoma // Oncologist. 2009. — Vol. 14. — № 4. — P. 425−432.
- Moccia A.A., Hoskins P., Klasa R. et al. Gemcitabine, dexamethasone and cisplatin (GDP): effective and well-tolerated salvage therapy for relapsed/ refractory Hodgkin lymphoma // Haematologica. 2010. — Vol. 95. — P. S28. (Abstr. P097).
- Molin D., Edstrom A., Glimelius I. et al. Mast cell infiltration correlates with poor prognosis in Hodgkin’s lymphoma // Br. J. Hematol. 2002. -Vol. 119.-P. 122−124.
- Moskowitz A.J., Yahalom J., Maragulia J. et al. Predicting response to salvage therapy in relapsed and refractory Hodgkin lymphoma // Haematologica. -2010. Vol. 95. — P. S27−28. (Abstr. P094).
- Nadali G., Tavecchia L., Zanolin E. et al. Serum level of the soluble form of the CD30 molecule indentifies patients with Hodgkin’s disease at high risk ofunforable outcome //Blood. 1998. — Vol. 91. — P. 3011−3016.
- Nieder C., Petersen S., Petersen C., Thames H.D. The challenge of p53 as prognostic and predictive factor in Hodgkin’s or non- Hodgkin’s lymphoma // Ann. Hematol. 2001. — Vol. 80. — P. 2−8.
- Oki Y., Pro B., Fayad L.E. et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma//Cancer. 2008. — Vol. 112.-P. 831−836.
- Oki Y., Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma // Leuk. Lymphoma. 2008. — Vol. 49 (5). — P. 883−889.
- Peggs K.S., Hunter A., Chopra R. et al Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation // Lancet. 2005. — Vol. 365. — P. 1934−1941.
- Raemaekers J.M.M. Treatment of stage I and II Hodgkin’s lymphoma // Haematology. 2006. — Vol. 2. — P. 161−165.
- Roach M., Brophy N., Cox R. et al. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin’s disease // J. Clin. Oncol. 1990. -Vol. 8.-P. 623−629.
- Robinson S.P., Sureda A., Canals C. et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma indentification of prognostic factors predicting outcome // Haematologica. 2009. — Vol. 94. -P.230−238.
- Rodriguez J., Rodriguez M.A., Fayad L. et al. ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin’s disease // Blood. 1999. -Vol. 93.-P. 3632−3636.
- Santoro A., Bredenfeld H., Devizzi L. et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study // J. Clin. Oncol. 2000. — Vol. 18. — P. 2615−2619.
- Santoro A., Magagnoli M., Spina M. et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma // Haematologica. 2007. — Vol. 92. — P. 35−41.
- Sarris A.H., Kliche K.O., Nadali G. Biologic factors in Hodgkin’s disease: a window into prognosis and a guide for investigational therapy // Leuk. Lymphoma. 2001. — Vol. 42 (suppl. 2). — P. 10.
- Scheid C., Topp M., Bornhauser M. et al. Allogenic stem cell transplantation for Hodgkin’s disease: a retrospective analysis of data from the German Stem Cell Transplantation Registry (DRST) // Haematologica. 2010. -Vol. 95. — P. S26. (Abstr. C089).
- Sirohi B., Cunningham D., Powles R. et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma//Ann. Oncol. 2008. — Vol. 19.-P. 1312−1319.
- Smolewski P., Niewiadomska H., Los E., Robak T. Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells- clinical and pathological implications in patients with Hodgkin’s disease // Int. J. Oncol. 2000. — Vol. 17. — P. 603−609.
- Sohier W.D., Wong R.K., Aisenberg A.C., Vinblastine in the treatment of advanced Hodgkin’s disease // Cancer. 1968. — Vol. 22. — P. 467−472.
- Sureda A. Reduced intensity allogeneic stem cell transplantaion for refractory/relapsed Hodgkin’s lymphoma. Preliminary results of an EBMT prospective trial? // Haematologica. 2007. — Vol. 92. — P. 92. (Abstr. 1064).
- Trumper L., Jung W., Dahl G. et al. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin’s disease // Ann. Oncol.- 1994. Vol. 5 (suppl. 1). — P. 93−96.
- Venkatesh H., Di Bella N., Flynn T.P. et al. Results of a phase II multicenter trial of singleagent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma // Clin. Lymphoma. 2004. — Vol. 5. — P. 110−115.
- Viviani S., Bonadonna G., Santoro A. et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results // J. Clin. Oncol. 1996. — Vol. 14. — P. 603−609.
- Viviani S., Bonfante V., Santoro A. et al. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin’s disease // Cancer. 1999. — Vol. 5. — P. 275−282.153
- Wirth A., Corry J., Laidlaw C. et al. Salvage radiotherapy for Hodgkin’s disease following chemotherapy failure // Int. J. Radiat. Oncol. Biol. Phys. -1997.-Vol. 39.-P. 599−607.
- Xerri L., Bouabdallah R., Camerlo J., Hassoun J. Expression of the p53 gene in Hodgkin’s disease: dissociation between immunohistochemistry and clinicopathological data. // Hum. Pathol. 1994. — Vol. 25. — P. 449−454.
- Younes A., Bartlett N.L., Leonard J. et al. Brentuximab Vedotin (SGN-35) for relapsed CD30-positive lymphomas // N. Engl. J. Med. 2010. — Vol. 363.-P. 1812−1821.
- Younes A., Cabanillas F., Malaughlin P.W. Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin’s disease // Ann. Oncol. 1996. — Vol. 7. — P. 1083−1085.
- Younes A., Romaguera J., Hagemeister F. et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin’s disease // Cancer. 2003. — Vol. 98.-P. 310−314.
- Zander T., Wiedenmann S., Wolf J. Prognostic factors in Hodgkin’s lymphoma // Ann. Oncol. 2002. — Vol. 13. (suppl. 1). — P. 67−74.
- Zinzani P.L., Bendandi M., Stefoni V. et al. Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease // Haematologia. 2000. — Vol. 85. -P. 926−929.W